J
Jens Bukh
Researcher at University of Copenhagen
Publications - 302
Citations - 22917
Jens Bukh is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Hepatitis C virus & Virus. The author has an hindex of 71, co-authored 270 publications receiving 21051 citations. Previous affiliations of Jens Bukh include Copenhagen University Hospital & Hvidovre Hospital.
Papers
More filters
Journal ArticleDOI
Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor
Judith M. Gottwein,Sanne B. Jensen,Stéphanie B. N. Serre,Lubna Ghanem,Troels K. H. Scheel,Tanja B. Jensen,Henrik Krarup,Nathalie Uzcategui,Lotte S. Mikkelsen,Jens Bukh +9 more
TL;DR: The developed HCV culture systems will facilitate studies benefitting from expression of genotype-specific NS4A in a constant backbone in the context of the complete viral replication cycle, including functional studies and evaluations of the efficacy of antivirals.
Journal ArticleDOI
Gender differences among patients with a single depressive episode.
TL;DR: Evidence is provided for a higher level of anxiety and neuroticism among females with a recent onset of depression, whereas other clinical characteristics of first-episode depression were equivalent between male and female patients.
Patent
Efficient cell culture system for hepatitis C virus genotype 7a
TL;DR: The 7a/JFH1 recombinants provided a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses as discussed by the authors, which showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/jFH1 reference virus.
Journal ArticleDOI
Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance.
Rodrigo Velázquez-Moctezuma,Rodrigo Velázquez-Moctezuma,Andrea Galli,Andrea Galli,Mansun Law,Jens Bukh,Jens Bukh,Jannick Prentoe,Jannick Prentoe +8 more
TL;DR: I696 is in the AR4A epitope, which has a high barrier to resistance, thus strengthening the rationale for its inclusion in rational HCV vaccine designs.
Journal ArticleDOI
Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
Christina Sølund,Henrik Krarup,Santseharay Ramirez,Peter Thielsen,Birgit Røge,Suzanne Lunding,Toke S Barfod,Lone Galmstrup Madsen,Britta Tarp,Peer Brehm Christensen,Jan Gerstoft,Alex Lund Laursen,Jens Bukh,Nina Weis +13 more
TL;DR: The cure rate after triple therapy in a routine clinical setting was 47%, which is substantially lower than in clinical trials, and resistance variants towards protease inhibitors were seen in 71% of patients failing therapy indicating that resistance could have an important role in treatment response.